Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis

Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein(1). One approach to addressing this challenge is to define frequently co-occurring mutations with KRAS, which themselves may l...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero, Rodrigo, Sayin, Volkan I., Davidson, Shawn M., Bauer, Matthew R., Singh, Simranjit X., LeBoeuf, Sarah E., Karakousi, Triantafyllia R., Ellis, Donald C., Bhutkar, Arjun, Sanchez-Rivera, Francisco J., Subbaraj, Lakshmipriya, Martinez, Britney, Bronson, Roderick T., Prigge, Justin R., Schmidt, Edward E., Thomas, Craig J., Goparaju, Chandra, Davies, Angela, Dolgalev, Igor, Heguy, Adriana, Allaj, Viola, Poirier, John T., Moreira, Andre L., Rudin, Charles M., Pass, Harvey I., Vander Heiden, Matthew G., Jacks, Tyler, Papagiannakopoulos, Thales
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677540/
https://www.ncbi.nlm.nih.gov/pubmed/28967920
http://dx.doi.org/10.1038/nm.4407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677540/
https://www.ncbi.nlm.nih.gov/pubmed/28967920
http://dx.doi.org/10.1038/nm.4407

Ejemplares similares